Company* (Country; Symbol) |
Product |
Description |
Indication |
Status (Date) |
| | ||||
AUTOIMMUNE | ||||
ILEX Oncology Inc. (ILXO) |
Campath (FDA-approved) |
Alemtuzumab; humanized monoclonal antibody directed against the CD52 antigen prevalent on leukemia and lymphoma cells |
Multiple sclerosis |
Clinical data showed Campath suppressed disease activity for a prolonged period in 36 patients with secondary, progressive MS (4/2) |
|
||||
CANCER | ||||
Access Pharmaceuticals Inc. (AMEX:AKC) |
AP5346 |
A DACH polymer platinate |
Ovarian cancer |
Company began a Phase I trial in France and the Netherlands (4/3) |
|
|
|||
PhotoCure ASA (Norway; OSE:PH) |
Metvix PDT (FDA-approved)
|
Photodynamic therapy; a cream that is absorbed into the cancer cells, followed by activation of the drug through illumination with a red light source called Curelight |
Actinic keratosis |
Company received Australian regulatory approval; Phase III data showed it to be efficacious in treating early squamous cell carcinoma (4/3) |
|
||||
CARDIOVASCULAR | ||||
Actelion Ltd. (Switzerland; SWX:ATLN) |
Tracleer |
An orally available dual endothelin receptor antagonist |
Pulmonary arterial hypertension |
Company submitted an NDA in Japan (4/8) |
|
||||
Endovasc Inc. (OTC BB:EVSC) |
Liprostin intravenously |
Alprostadil; a liposomal formulation of the prostaglandin E1(a) infused claudication |
Critical limb ischemia and intermittent |
Company plans to initiate a Phase II dose-ranging trial in Europe and Mexico (4/23) |
|
|
|||
INFECTION | ||||
Serono SA (Switzerland; NYSE:SRA) |
Serostim |
Somatropin (rDNA origin) for injection |
AIDS wasting |
The Committee for Proprietary Medicinal Products recommended not granting marketing authorization for Serostim in the European Union (4/30) |
|
||||
Xenova Group plc (UK; XNVA) |
TA-CIN and TA-HPV |
Vaccines |
Human papil-lomavirus-associated ano-genital intraepithelial neoplasia |
Phase II data involving 29 patients in the UK showed the combination tion of the vaccines was safe and well tolerated and demonstrated clear clinical responses, even in women with longstanding disease (4/14) |
|
|
|||
MISCELLANEOUS | ||||
CollaGenex Pharmaceuticals Inc. (CGPI) |
Periostat (FDA-approved) |
Doxycyline tablets 20 mg |
Periodontal disease |
Company was granted Swiss marketing approval (4/1); company received Canadian regulatory approval (4/3) |
|
|
|||
Isis Pharmaceuticals Inc. (ISIS) |
ISIS 2302 |
Alicaforsen; an antisense inhibitor of intercellular adhesion molecule-1 |
Ulcerative colitis |
Company initiated a Phase II trial (4/8) |
| | ||||
Notes: | ||||
* Privately held | ||||
Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market. | ||||
AMEX = American Stock Exchange; NYSE = New York Stock Exchange; OSE = Oslo Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SWX = Swiss Stock Exchange | ||||
